Back to Search
Start Over
Nouvelle thérapie antiangiogénique indépendante du VEGF qui cible le récepteur CD160
- Source :
- médecine/sciences, médecine/sciences, EDP Sciences, 2012, 28 (1), pp.37-38. ⟨10.1051/medsci/2012281013⟩
- Publication Year :
- 2012
- Publisher :
- HAL CCSD, 2012.
-
Abstract
- Nouvelle therapie antiangiogenique independante du VEGF qui cible le recepteur CD160 Philippe Le Bouteiller1, Julie Tabiasco1, Jerome Giustiniani2, Armand Bensussan3 1 Inserm UMR 1043, CNRS UMR 5282, universite de Toulouse, centre de physiopathologie de Toulouse-Purpan, hopital Purpan, Bât. A, BP 3028, 31024 Toulouse Cedex 3, France ; 2 Institut Jean Godinot, BP171, 51056 Reims Cedex, France ; 3 Inserm UMR 976, pavillon Bazin, hopital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France philippe.le-bouteiller@inserm.fr armand.bensussan@inserm.fr
- Subjects :
- 0303 health sciences
business.industry
[SDV]Life Sciences [q-bio]
GPI-Linked Proteins
General Medicine
ANTIGENS CD
medicine.disease
Molecular biology
General Biochemistry, Genetics and Molecular Biology
3. Good health
03 medical and health sciences
0302 clinical medicine
Antibodies monoclonal
Medicine
[SDV.IMM]Life Sciences [q-bio]/Immunology
business
Fibrosarcoma
ComputingMilieux_MISCELLANEOUS
030304 developmental biology
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 07670974 and 19585381
- Database :
- OpenAIRE
- Journal :
- médecine/sciences, médecine/sciences, EDP Sciences, 2012, 28 (1), pp.37-38. ⟨10.1051/medsci/2012281013⟩
- Accession number :
- edsair.doi.dedup.....e118a1ba5f768db87a6eb8a58a990a0f